Skip to main content

Hydroxychloroquine Dose and Risk for Incident Retinopathy A cohort study in Annals of Internal Medicine shows that hig

Social Author Name
Dr. John Cush
Tweet Content
Hydroxychloroquine Dose and Risk for Incident Retinopathy A cohort study in Annals of Internal Medicine shows that higher hydroxychloroquine doses was associated with progressively greater risk for incident retinopathy. https://t.co/DZ2UxDKgUD https://t.co/tFtNZc1Eza

Poorer health outcomes for at-risk patients with fractures People at high risk of fracture are less likely to receive

Social Author Name
Dr. John Cush
Tweet Content
Poorer health outcomes for at-risk patients with fractures People at high risk of fracture are less likely to receive treatment for the underlying osteoporosis and also have poorer health outcomes. https://t.co/XmFcnBf6US https://t.co/mgAkb0NLBv

Rx failures w/ nonmedical switching of biosimilars may be Nocebo effect. 140 #RA pts, 51 non-switchers & 89 switcher

Social Author Name
Dr. John Cush
Tweet Content
Rx failures w/ nonmedical switching of biosimilars may be Nocebo effect. 140 #RA pts, 51 non-switchers & 89 switchers. Non-switchers more likely to improve than switchers (68 vs 26%, p < 0.001) and less likely to worsen (1% vs 9%, p < 0.01). https://t.co/w8lnv1V5Pi https://t.co/iT2RkkSosl
PsA Til Death Do Us Part (1.20.2023)

Dr. Jack Cush reviews the highlights from the past week on RheumNow.com.

Naltrexone is indicated in opioid or EtOH dependence - not pain; yet it has wide off-label uses. Shown to be equal to El

Social Author Name
Dr. John Cush
Tweet Content
Naltrexone is indicated in opioid or EtOH dependence - not pain; yet it has wide off-label uses. Shown to be equal to Elavil in Rx of painful DM neuropathy; Little data from PBO RCTs in FM. Unclear how naltrexone modulates pain https://t.co/YZvfbHy9KJ https://t.co/6k9LfQSp1A

What RheumNow Live attendees say about our meeting: "Great format w/shorter lectures, clinical content, good interface

Social Author Name
Dr. John Cush
Tweet Content
What RheumNow Live attendees say about our meeting: "Great format w/shorter lectures, clinical content, good interface for audience participation to ask questions, and on-demand availability of videos post-meeting." Join us! https://t.co/AO0bqP5p54 @Janetbirdope @JoelKreme… https://t.co/d9ZhIbddgh
AS, but not PsA, has Increased Mortality Risk

Inflammatory disorders are often accompanied by an increased mortality risk, either from secondary malignancy, infection or cardiovascular disease. A recent meta-analysis showed a significantly increased risk of overall mortality in ankylosing spondylitis (AS) but not psoriatic arthritis (PsA), largely associated with cardiovascular-specific mortality .

As individual studies on mortality in PsA and AS have yielded conflicting results, a metanalysis was performed and included 19 studies (11 of PsA, 7 of AS, 1 of both).

New Guideline: Vaccinations OK for Rheum Patients Nearly all available vaccines can be given to people w/ rheumatologi

Social Author Name
Dr. John Cush
Tweet Content
New Guideline: Vaccinations OK for Rheum Patients Nearly all available vaccines can be given to people w/ rheumatologic diseases, according to a new guideline from the ACR, though the timing for their administration and dosing may need adjustment. https://t.co/kHWyrmjkuw https://t.co/LrcFrZR2TO

PsART-ID study of 1216 #PsA pts showed PsA mortality to be similar to general population, but during pandemic PsA mortal

Social Author Name
Dr. John Cush
Tweet Content
PsART-ID study of 1216 #PsA pts showed PsA mortality to be similar to general population, but during pandemic PsA mortality doubled (5.1 vs 10.86 pandemic) with a higher increase in females (2.9 vs 8.72) than males (9.07 vs 14.73) https://t.co/AzhjOlW8vh https://t.co/YF7OlEh0sK
Subscribe to
×